Protagenic Therapeutics, Inc.
PTIX
$3.44
-$0.08-2.27%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -23.26% | 156.96% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -11.87% | 151.99% | |||
| Operating Income | 11.87% | -151.99% | |||
| Income Before Tax | 7.32% | -142.46% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 7.32% | -142.46% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 7.32% | -142.46% | |||
| EBIT | 11.87% | -151.99% | |||
| EBITDA | 11.96% | -154.98% | |||
| EPS Basic | 21.66% | -77.38% | |||
| Normalized Basic EPS | 25.52% | -86.55% | |||
| EPS Diluted | 21.66% | -77.38% | |||
| Normalized Diluted EPS | 25.52% | -86.55% | |||
| Average Basic Shares Outstanding | 18.32% | 36.69% | |||
| Average Diluted Shares Outstanding | 18.32% | 36.69% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||